Analysts See $0.07 EPS for FTD Companies, Inc. (FTD); Supernus Pharmaceuticals (SUPN) Shorts Up By 16.91%

February 28, 2018 - By Vivian Currie

Analysts expect FTD Companies, Inc. (NASDAQ:FTD) to report $0.07 EPS on March, 13.They anticipate $0.33 EPS change or 82.50% from last quarter’s $0.4 EPS. FTD’s profit would be $1.93M giving it 22.21 P/E if the $0.07 EPS is correct. After having $-0.37 EPS previously, FTD Companies, Inc.’s analysts see -118.92% EPS growth. The stock decreased 1.89% or $0.12 during the last trading session, reaching $6.22. About 99,763 shares traded. FTD Companies, Inc. (NASDAQ:FTD) has declined 26.52% since February 28, 2017 and is downtrending. It has underperformed by 43.22% the S&P500.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had an increase of 16.91% in short interest. SUPN’s SI was 4.08M shares in February as released by FINRA. Its up 16.91% from 3.49 million shares previously. With 993,000 avg volume, 4 days are for Supernus Pharmaceuticals Inc (NASDAQ:SUPN)’s short sellers to cover SUPN’s short positions. The SI to Supernus Pharmaceuticals Inc’s float is 8.23%. The stock decreased 2.06% or $0.8 during the last trading session, reaching $38.1. About 759,608 shares traded or 29.52% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since February 28, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 36 analyst reports since August 26, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of SUPN in report on Monday, November 6 with “Buy” rating. Jefferies maintained it with “Buy” rating and $51.0 target in Tuesday, September 5 report. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Buy” rating by FBR Capital on Monday, November 20. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Wednesday, November 8 by B. Riley & Co. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Outperform” rating by Northland Capital on Wednesday, October 28. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Neutral” rating given on Monday, July 18 by Piper Jaffray. Cowen & Co maintained the stock with “Buy” rating in Monday, October 23 report. The stock has “Buy” rating by Jefferies on Thursday, August 3. The firm has “Buy” rating by Cowen & Co given on Tuesday, September 19. The firm has “Buy” rating given on Monday, September 18 by Cantor Fitzgerald.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $1.95 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 34.67 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Since September 7, 2017, it had 0 buys, and 10 sales for $15.31 million activity. Shares for $249,303 were sold by Bhatt Padmanabh P.. Another trade for 95,000 shares valued at $4.43 million was sold by Schwabe Stefan K.F.. The insider Vaughn Victor sold 15,000 shares worth $630,650. $2.18M worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares were sold by PATRICK GREGORY S.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.34, from 1.32 in 2017Q2. It fall, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Alphaone Invest Service Limited Co has invested 1.77% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Cortina Asset Lc holds 0.15% or 93,600 shares. Hodges Management holds 328,945 shares or 0.89% of its portfolio. Pnc Gru Incorporated holds 0.01% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 224,841 shares. Castleark Management Lc reported 316,940 shares. Mufg Americas Hldg reported 781 shares. Great West Life Assurance Communication Can reported 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Virginia Retirement Systems Et Al invested in 52,000 shares. Barclays Plc, United Kingdom-based fund reported 3,308 shares. Geode Mgmt Limited Liability has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). 32,000 were accumulated by U S Global Invsts. Schroder Inv Management Group reported 8,464 shares. Spectrum Mngmt Grp Inc stated it has 15 shares or 0% of all its holdings. The Minnesota-based White Pine Capital Lc has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Principal Fin Grp Inc Inc stated it has 0.02% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

FTD Companies, Inc., through its subsidiaries, operates as a floral and gifting firm primarily in the United States, Canada, the United Kingdom, and the Republic of Ireland. The company has market cap of $171.34 million. The firm operates through four divisions: Consumer, Provide Commerce, Florist, and International. It currently has negative earnings. It provides floral arrangements and plants, gifts, and related services and products to consumers, retail florists, and other retail locations and companies.